This dual mechanism is why tirzepatide consistently outperforms every other weight loss medication in head-to-head clinical evidence
The risk of incident atrial fibrillation in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors: a nationwide cohort study
The legal and safety landscape around compounded GLP-1 medications changed dramatically between late 2024 and 2026
Why GLP-1 Drugs May Increase Gout Risk The study also found a slightly higher risk of gout among GLP-1 users
That amounts to $56 in savings each month
These findings are further supported by another sub-analysis of SURMOUNT1, which reported a 33.9% (8.2% for placebo) reduction in fat mass and a 10.9% (2.6% for placebo) reduction in lean mass by week 72, with approximately 75% of weight loss attributable to fat mass, consistent across clinically relevant subgroups [68]